strategic alliance

We all knew that the news we wait for would not be part of the quarterly.

One has to dissect the announcement in the usual fashion to determine what are most likely the next steps towards a licence deal.

Dr Matthew McIldowie is working with various groups in the FMCG to evaluate the enhancement percentages for delivery when using our FIM or em-patch.
This means that the FMCG and OBJ staff are already sharing office space.

Evidently, the FMCG is the most progressed within our negotiating partners.
Interesting to note that the Strategic Alliance, not the proposed alliance, is progressing well.
One needs to be alert to such word choices as it indicates that the Strategic Alliance is not something which might possibly be created eventually, but something which is decided upon already.
This point was critically viewed by many and has been answered.
What that also means is that OBJ and the FMCG have spent several years together testing the technology in general and have entered their partnership to now evaluate specific drugs from that FMCG.

One does not extend the resources of the internal labs if no partner pays for all this.
The next quaterly should show the FMCG paying for this enlargment of resources.

Further news of the Strategic Alliance will arrive outside the quaterly and when technical evaluation will show results.

I would expect further news regarding the Strategic Alliance within this year.


3M has agreed to be manufacturer for OBJ patches, the MTA is concluded and OBJ and the FMCG can build on 3M's experties to have top quality products for their drug deliveries.
The focus of OBJ is obviously towards Europe, which was evident after Hammond took his office in the UK.
Research from the enlarged lab here will be further augmented in the UK and Europe, which most likely means that OBJ research and products will be implemented into the research lab of the FMCG in Europe.

The biopartnering conference was indeed presented by Dr Hammond, probably created more avenues for additional partnerships.

The Strategic Alliance with the FMCG will have other parties follow suit in time.



Whoever expected a dynamite ann within the quaterly was obviously misled by false expectations.
If anybody had doubts where our first revenues will be coming from, this query has been answered.
The FMCG will be named, most probably, in the next ann regarding progress on the Strategic Alliance.

Many posters here treated the quaterly as a major milestone in OBJs progress. This is a questionable approach and only had to disappoint.
The meaningful ann will be presented on its own and will be, in all likelihood, a formal deal, or its preludes, between the FMCG and OBJ.

The only outstanding concern is the time frame within which that can be achieved.
To help there, please check the progress for the Altea deal.

2007, agreement with unnamed company, sounds familiar?

http://www.in-pharmatechnologist.com/Materials-Formulation/Altea-s-skin-patches-set-to-spread-transdermal-drug-delivery

2 years later, the upfront licence payment arrives and the pharmaceutical company in the agreement finally has a name:

http://www.techconnect.org/news/press/item.html?id=216


Our first FMCG contact was 2007, do the math and you will probably come to the same conclusion as I did myself some time ago that we are around the corner for an ann which presents the name of the mysterious FMCG and will include a licence upfront payment.